Dr. James F. Howard Jr., Professor of Neurology at the University of North Carolina at Chapel Hill School of Medicine, has played a pivotal role as Principal Investigator in the ADAPT SERON study\u2014marking a major advancement in the treatment of generalized myasthenia gravis (gMG). The study, conducted by global immunology company argenx, demonstrated that VYVGART\u00ae (efgartigimod alfa-fcab) significantly improves disease activity in patients with AChR-Ab seronegative gMG.<\/p>\n
\u201cThe results of the ADAPT SERON study, the largest study to date of AChR-Ab seronegative gMG, confirm that VYVGART now has the potential to be a targeted, effective, safe, and necessary treatment for patients living with gMG, regardless of autoantibody status,\u201d said James F. Howard Jr., M.D., Professor of Neurology (Neuromuscular Disease), Medicine and Allied Health, Department of Neurology, The University of North Carolina at Chapel Hill School of Medicine and Principal Investigator for the ADAPT SERON trial. \u201cPaired with our existing knowledge, these data demonstrate that pathogenic IgGs are underlying drivers of gMG across patient subtypes. This is a critical advancement in the management of this debilitating and unpredictable disease for patients with limited treatment options.\u201d<\/span><\/p>\n The ADAPT SERON trial is the first global Phase 3 study to show clinically meaningful improvements across all three AChR seronegative subtypes\u2014MuSK+, LRP4+, and triple seronegative. With a statistically significant primary endpoint (p=0.0068), the findings support a planned submission to the FDA for label expansion by the end of 2025. Dr. Howard also served as the global lead for the primary phase 3 trial that led to regulatory approval of this drug in the US, Europe, Japan, and China.<\/p>\n Dr. Howard emphasized that the data reinforce the role of pathogenic IgGs as underlying drivers of gMG across subtypes, offering new hope for patients who previously had few therapeutic options.<\/p>\n The ADAPT SERON study looked at how well the medication\u00a0VYVGART<\/strong>\u00a0works for people with a rare form of myasthenia gravis (gMG) who don\u2019t have the common AChR antibodies. This includes people with MuSK+, LRP4+, or no detectable antibodies at all (triple seronegative).<\/p>\n
\nAbout the ADAPT SERON Study<\/h3>\n